Navigation Links
Aureus Pharma Releases New Unified Knowledge Database
Date:8/18/2008

AurSCOPE(R) Global Pharmacology Space and Drug Target Knowledge Databases

Related to Nuclear Receptors and Proteases

PARIS, August 18 /PRNewswire/ -- Aureus Pharma, a leading provider of knowledge management solutions that accelerate life sciences discovery, announced today the release of three new AurSCOPE(R) Target knowledge databases. The new offerings include knowledge databases for the important drug targets Nuclear Receptor and Protease, as well as the centralized product AurSCOPE(R) Global Pharmacology Space (AurSCOPE(R) GPS). AurSCOPE GPS comprises all of the pharmaceutically important therapeutic targets including G-Protein coupled receptors (GPCR), kinases, ion channels, nuclear receptors and proteases.

Nuclear receptor proteins are integral to critical metabolic processes and implicated in diseases including diabetes, cancer, and heart disease. Likewise, proteases are a major focus for therapeutic intervention being linked to viral diseases including HIV, inflammation and neurogenerative disorders.

AurSCOPE GPS and other AurSCOPE Knowledge databases streamline discovery efforts with thorough assessment of selectivity and off-target effects at the earliest stages of the drug discovery pipeline.

"The release of AurSCOPE Global Pharmacology Space (GPS), Nuclear Receptor and Protease represents an exciting milestone for Aureus Pharma. These powerful new products considerably extend Aureus' knowledge management solution by providing our pharmaceutical customers unique access to the druggable therapeutic target space." said Jason Theodosiou, President and CEO of Aureus Pharma. "Using AurSCOPE Knowledge databases, researchers easily employ knowledge-driven hypotheses to drive better informed decisions during drug discovery."

Aureus experts will demonstrate AurSCOPE GPS, AurSCOPE Nuclear Receptor and AurSCOPE Protease products at the American Chemical Society (ACS) meeting in Philadelphia, PA August 18th -21st.

About Aureus Pharma

Aureus Pharma headquartered in Paris, France is a privately held

knowledge management based solutions provider for the life sciences

industry. Aureus Pharma accelerates new drug discovery by providing

knowledge databases which contain high quality quantitative information

for both chemistry and biology. Researchers gain rapid access to

knowledge for important drug target classes as well as ADME/Tox topics.

The information contained in the Aureus Pharma system is of primary

importance to aid in lead discovery and optimization as well as to

build predictive models. For further information on how Aureus Pharma

helps researchers turn data into discovery visit

http://www.aureus-pharma.com

Media Contact

Mary E. Donlan, Ph.D.

Director of Marketing

Aureus Pharma

Phone:+33-1-40-18-57-59 / +33-6-76-19-51-77

mary.donlan@aureus-pharma.com


'/>"/>
SOURCE Aureus Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Aureus Pharma Releases AurPROFILER(R) - a New and Powerful Pharmacology Profiling Solution
2. Aureus Pharma Announces Date of 2008 Annual User Symposium
3. QSB Anti-Virulence Platform Inhibits Biofilm Formation by Staphylococcus Aureus MRSA and Candida sp
4. Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
5. New ActivePure Technology Proven To Reduce Exposure to Methicillin Resistant Staphylococcus Aureus (MRSA)
6. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
7. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
8. Catalyst Pharmaceutical Partners Reports Second Quarter 2008 Financial Results
9. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
10. Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
11. Ondine Biopharma Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, into ... for over 35 years, is proud to add Target to its list of ...
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
Breaking Biology Technology:
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
Breaking Biology News(10 mins):